首页> 外文期刊>The Internet Journal of Surgery >Evaluation Of The Efficacy And Safety Of Butorphanol Nasal Spray In The Management Of Postoperative Pain
【24h】

Evaluation Of The Efficacy And Safety Of Butorphanol Nasal Spray In The Management Of Postoperative Pain

机译:布托啡诺鼻喷剂治疗术后疼痛的疗效和安全性评价

获取原文
获取外文期刊封面目录资料

摘要

Objective: To evaluate the efficacy and safety of Butorphanol nasal spray in the management of postoperative pain in patients with orthopedic surgery. Materials and Methods: This prospective, open and non-comparative study was conducted on outpatient basis by qualified investigators at three different centers. A total of 105 patients with postoperative pain were enrolled in the study. The enrollment of the patients was as per inclusion/exclusion criteria. After obtaining informed consent they were individually interviewed, examined, investigated and treated as per study protocol. The treatment included one dose of Butorphanol nasal spray in each nostril equivalent to 2 mg of Butorphanol for the period of 24 hours. They were followed up at the end of 1 hour, 2, 4, 6, 12 and 24 hours. They were asked to avoid any other concomitant medication without the knowledge of the treating physician. Results: A significant improvement in the pain score of the patients was observed at the end of 15 min. The treatment with Butorphanol nasal spray is associated with very few adverse events. Tolerability of the treatment was also reported to be excellent in the majority of the study population. Nasal administration with faster absorption offers advantages of rapid onset and patient control with relative ease of administration. It bypasses gastrointestinal and hepatic presystemic elimination and is also applicable in patients with nausea and vomiting. Conclusion: The present study concludes that Butorphanol nasal spray is highly effective, safe and well tolerable in postoperative pain management and seems to be a good alternative to both oral and injectable Butorphanol treatment. Introduction Pain is as old as human being and is becoming more and more troublesome to mankind with greater incidences of medical surgeries. Many surgical procedures are associated with extreme painful conditions which are associated with physical, psychological and immunological depression. The field of postoperative pain management is being given more and more attention as it is an essential component of the care of surgical patients. Inadequate pain control, apart from being inhumane, may result in increased morbidity or mortality. The overriding principle of postoperative pain management is to provide a general background of analgesia that is sufficient to permit normal activities, along with additional analgesic supplements to cover any painful activity (dynamic pain). Breaking the pain cycle at an early stage may prevent central sensitization and, consequently, chronic pain. A second objective is to improve surgical outcome with the goals of enabling early ambulation and recovery of gastrointestinal function which in turn reduce cardiopulmonary morbidity, psychological stress, anxiety and insomnia; and preventing a poor learned response to future pain episodes.A wide area of postoperative pain management is covered by afferent neural blockade with local anesthetics. Next in order of effectiveness are high dose opioids, epidural opioids and clonidine, patient controlled opioid therapy and Non-Steroidal Anti-Inflammatory Agents.Butorphanol is a synthetic opioid derivative possessing agonist-antagonist activity at opioid μ2-receptors and additional agonist activity at opioid κ-receptors. The analgesic efficacy of Butorphanol is comparable with that of Morphine, Mepiridine, and other opioids. However, the safety concerns with Butorphanol are much lower compared to other opioids, especially the addiction potential. The 14 years of safe and effective use of Butorphanol injection make Butorphanol the ‘drug of choice' in a number of painful conditions.In recent years, nasal drug delivery systems emerged as a suitable alternative for the common route of intravenous and oral dosing. Nasal administration may offer advantages such as ease of administration, rapid onset and patient control. It bypasses gastrointestinal and hepatic presystemic elimination and is applicable in
机译:目的:评价丁烷酚鼻喷雾剂在骨科手术患者术后疼痛管理中的有效性和安全性。材料和方法:这项前瞻性,开放性和非对比性研究是由三个不同中心的合格研究人员在门诊进行的。本研究共纳入105名术后疼痛患者。患者的入组按照纳入/排除标准。在获得知情同意后,按照研究方案对他们进行单独访谈,检查,调查和治疗。该治疗包括在每只鼻孔中注射一剂布托啡诺鼻喷雾剂,相当于2毫克布托啡诺,持续24小时。在1小时,2、4、6、12和24小时结束时进行随访。他们被要求避免在治疗医师不知情的情况下避免使用任何其他伴随药物。结果:在15分钟结束时,患者的疼痛评分明显改善。布托啡诺鼻喷雾剂的治疗几乎没有不良反应。据报道,在大多数研究人群中,治疗的耐受性也非常好。经鼻吸收更快的鼻腔给药具有起效快和患者控制的优点,并且给药相对容易。它绕过了胃肠道和肝脏的系统性清除,也适用于恶心和呕吐的患者。结论:本研究得出结论,布托啡诺鼻喷雾剂在术后疼痛管理中非常有效,安全且耐受性良好,似乎是口服和注射式布托啡诺治疗的良好选择。引言疼痛与人类一样古老,并且随着越来越多的医疗手术发生,人类正变得越来越麻烦。许多外科手术程序都与极度痛苦的状况有关,而极度痛苦的状况与身体,心理和免疫抑制有关。术后疼痛管理领域越来越受到重视,因为它是外科手术患者护理的重要组成部分。除不人道之外,疼痛控制不力还可能导致发病率或死亡率增加。术后疼痛处理的首要原则是提供足以允许正常活动的止痛一般背景,以及额外的止痛补充剂以覆盖任何痛苦的活动(动态疼痛)。尽早打破疼痛循环可能会阻止中枢性致敏作用,从而预防慢性疼痛。第二个目标是改善手术结果,其目标是能够及早移动并恢复胃肠功能,从而减少心肺疾病,心理压力,焦虑和失眠。并在局部麻醉药的传入神经阻滞下覆盖了广泛的术后疼痛管理。其次是有效性的大剂量阿片类药物,硬膜外阿片类药物和可乐定,患者控制的阿片类药物治疗和非甾体类抗炎药.Butorphanol是一种合成的阿片类药物衍生物,在阿片样物质μ2-受体上具有激动剂-拮抗剂活性,在阿片样物质上具有额外的激动剂活性。 κ受体。布托啡诺的镇痛效果可与吗啡,甲哌丁啶和其他阿片类药物相媲美。但是,与其他阿片类药物相比,布托啡诺的安全性要低得多,尤其是成瘾的可能性。 14年安全有效地使用Butorphanol注射剂使Butorphanol在许多痛苦的情况下成为“首选药物”。近年来,鼻给药系统已成为静脉和口服给药常用途径的合适替代品。鼻给药可以提供诸如给药容易,起效快和患者控制的优点。它绕过胃肠道和肝脏的系统性消除,适用于

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号